Among the different vaccination approaches, DNA/RNA vaccination represents a promising means in particular for the induction of effective cellular immune responses conferred by CD8-positive T lymphocytes. To achieve such immune responses, there is a need for novel delivery systems that allow the introduction of nucleic acids to the cytosol of immune cells. We show, for the first time, the delivery of functional DNA and messenger RNA (mRNA) to mammalian antigen-presenting cells, including murine macrophages and human dendritic cells, using the yeast Saccharomyces cerevisiae as the delivery vehicle. After transfer of the particular nucleic acid, subsequent antigen processing and presentation were demonstrated in a human system. Remarkably, release of DNA/mRNA does not require additional 'helper' proteins such as listeriolysin. In conclusion, the yeast-based system described here is superior to many bacterial and viral systems in terms of efficacy, safety and targeting suggesting 'mycofection' as a promising approach for the development of a novel type of live vaccines.
INTRODUCTION
The development of effective, economic and safe vaccines is still a major challenge in today's medicine. In particular need are vaccines that efficiently induce CD8-positive cytotoxic T lymphocytes (CTL), which are essential to resist several bacterial and many viral infections such as HIV and HCV, as well as to eliminate tumor cells. Consequently, CTL induction is an important goal in current vaccination strategies. As the efficient induction of CTL requires presentation of antigen-derived peptides via the major histocompatibility complex class I (MHC I) pathway, the antigen of interest should ideally be produced within the cytosol of an antigen-presenting cell (APC). Accordingly, DNA/RNA vaccination has become the most promising strategy for inducing cellmediated immunity. [1] [2] [3] To do so, several approaches have been described reaching from classical DNA vaccination up to the delivery of antigenencoding DNA or RNA by viruses or virulence-attenuated bacteria. Among these bacteria, most of the strains that have been used for antigen delivery belong to the large group of invasive enteric bacterial pathogens such as Escherichia coli, Shigella, Salmonella or Listeria. 4 Hitherto, several of these attenuated bacteria have been exploited to deliver heterologous antigens to mammalian cells as functional DNA or messenger RNA (mRNA) to be expressed in the infected host cell. [4] [5] [6] [7] However, although a number of studies have indicated the principle feasibility of this approach, convincing results of clinical trials are still missing. 8 Furthermore, bacteria often contain highly toxic cellular components such as lipopolysaccharides (gram-negative bacteria) or super antigens (many gram-positive bacteria), which detract them from being used in humans for safety concerns or at least diminish the acceptance of a putative vaccine. Further, the induction of a vectorneutralizing immune response is observed in many cases when using the same vector system for repeated vaccinations.
Per se, several attributes qualify yeast as a novel, promising DNA/ RNA vaccine candidate: yeast is known to elicit adjuvant effects by stimulating innate immune responses by structural cell wall components and to enhance crosspresentation of antigens. 9, 10 Yeast has been repeatedly shown to generate adaptive (including cell-mediated) immune responses in mice [11] [12] [13] [14] [15] [16] [17] [18] [19] and also in humans. 20 In contrast to the majority of attenuated bacteria and mammalian viruses (which are already under investigation as DNA/RNA carriers, for example, Listeria), several yeast genera possess the GRAS ('generally regarded as safe') status, which would facilitate the approval of a yeast-based vaccine considerably. It is devoid of endotoxins and super antigens, and most strains are, due to the tremendous experience in using yeast in genetics and biotechnology for many years, accessible to genetic modifications allowing among others the development of multivalent vaccines and/or the modulation of immune responses. Yeast, although being a genuine eukaryote, harbors the advantages of a single-cell microorganism, which is easy and safe to handle (that is, small size, easy cultivation and fast cell growth). Moreover, recombinant yeast can be given orally as yeast cells are able to protect the antigenencoding nucleic acid from degradation by acidic pH and/or nucleases during passage through stomach and gut. Furthermore, yeast cells are efficiently taken up by M cells 21 and may subsequently deliver their nucleic acid load to professional APCs in Peyer's patches, an important prerequisite for the induction of a mucosal immune response.
Here, we report on the development of S. cerevisiae as a delivery vehicle for nucleic acids. We show, for the first time, that recombinant yeast can deliver both functional DNA and mRNA to mammalian APCs, including human monocyte-derived dendritic cells (DCs), leading to efficient model gene (enhanced green fluorescent protein (eGFP)) expression, as well as antigen processing and presentation of the human cytomegalovirus (CMV) phosphoprotein pp65. Thus, the yeast-based carrier system established in this study has the potential to be developed into a novel kind of live vaccine.
RESULTS

Characterization of the delivery strains
In order to test the capacity of recombinant yeast to deliver functional nucleic acids to mammalian APCs, we constructed several strains based on S. cerevisiae S86c, which transport DNA or mRNA either to the murine macrophage-like cell line IC21 or to human DCs (corresponding plasmids summarized in Table 1 ). For delivery experiments, a codon-optimized GFP variant (eGFP) was used as a model protein for the expression in mammalian cells. To enhance translation in mammalian cells and prevent translation in yeast (see below), an internal ribosomal entry site (IRES) of the encephalomyocarditis virus was cloned upstream of eGFP in the delivery plasmids. For DNA delivery, we chose the CMV promoter, which mediates efficient transcription in a variety of mammalian cells. For mRNA delivery, we tested yeast promoters with different properties: the constitutive yeast phosphoglycerate kinase promoter (PGK) mediates eGFP expression in yeast before engulfment by APCs. For inducible mRNA expression within APC, the promoters of the yeast malate synthase (MLS1) and isocitrate lyase (ICL1) were used. Both promoters are derived from genes of the yeast glyoxylate cycle and therefore can be induced in vivo as a consequence of growth on a short-length carbon source (Figure 1a ) or within phagolysosomes after ingestion by murine macrophages. 22, 23 In a preliminary experiment, we found this observation also to be true for the ingestion of yeast cells by IC21 macrophages as well as human DCs (Figure 1b) . Interestingly, and in contrast to IC21 cells where both promoters are upregulated in rather equal amounts, we observed an earlier and much stronger induction of ICL1 in comparison with MLS1 in DCs.
Recombinant yeast cells deliver functional DNA and mRNA to murine macrophages To establish a delivery system for nucleic acids based on recombinant yeast as a carrier, 1Â10 5 IC21 macrophages were seeded in 24-well plates and allowed to adhere for 8 h. To determine the optimal yeast:macrophage ratio that allowed complete uptake of the yeast cells, S. cerevisiae S86c cells expressing eGFP were added at different multiplicities of infection (MOI). The uptake was followed microscopically, and green fluorescence was quantified 16 h post infection (p.i.) by flow cytometry after detachment of the IC21 macrophages. In this system, the optimal MOI was shown to be 7, yielding about 60% eGFP-positive macrophages (Supplementary Figure 1) . MOIs 47 exceeded the uptake capacity of the macrophages resulting in microscopically detectable yeast cells outside the IC21 cells. Thus, to compare the different yeast strains, we used MOI 7 in all further experiments. Notably, at this and also at higher MOI, yeast did not show any toxic effect on APCs (Figure 1c and data not shown).
Next, we determined the time of optimal eGFP expression within IC21 macrophages. Yeast cells carrying plasmids for DNA or mRNA delivery were added, and macrophages were tested at different time points for eGFP expression by flow cytometry. eGFP expression in IC21 cells was already detectable as early as 8 h p.i., reached a maximum at 16 h p.i. and declined afterwards, independent of the kind of nucleic acid delivered (Figure 1d ). Microscopical analysis revealed that a complete uptake of yeast cells required about 8-10 h, a fact that is also reflected by high standard deviations obtained at 8 h p.i. Accordingly, to ensure complete removal of all yeast cells and to allow direct comparison of the different strains, eGFP expression was quantified 16 h p.i. in all further experiments.
After loading IC21 macrophages with DNA or mRNA delivery strains, translation of the model antigen takes place within the mammalian cells To demonstrate that the observed eGFP expression occurred after transcription and/or translation of the eGFP gene in mammalian cells, we performed several control experiments. As yeast and murine IC21 cells are both eukaryotes, we could not use specific inhibitors of yeast transcription but only inhibitors that likewise affected yeast and mammalian RNA-PolII. However, to perform a suitable control experiment, we placed the eGFP gene lacking an IRES sequence under CMV promoter control. If the promoter had any transcriptional activity, we would be able to detect a green fluorescence as eGFP lacking IRES is translatable in yeast (see below). Using such a control, we initially confirmed by northern blotting that the CMV promoter is not transcriptionally active in S. cerevisiae S86c (Figure 2a) ; the same was true for eGFP variants containing an additional upstream IRES sequence, which was used for delivery studies (data not shown). , an observation that is also in line with a previous report. 24 Consequently and as expected, translation of both DNA and mRNA could be blocked by cycloheximide ( Figure 2d ). Thus, our data clearly indicate that any eGFP expression after DNA/ mRNA delivery is based on eGFP transcription/translation in mammalian cells and not in yeast. Yeast-based DNA/mRNA delivery B Walch et al ( Figure 3b ). Delivery of translation-competent mRNA yielded 31% transfected macrophages after constitutive mRNA expression and 37% for inducible mRNA formation under transcriptional control of the MLS1 promoter. The highest numbers with up to 42% were obtained with the inducible ICL1 promoter. Thus, in IC21 cells, constitutive formation of mRNA in yeast before engulfment by APCs is slightly less effective than inducible mRNA transcription; there was no obvious difference among the inducible promoters tested. In order to simulate in vivo conditions, we applied our delivery strategy also to human DCs, the most important cells for the induction of an adaptive immune response. For DCs, in contrast to IC21 cells, we determined MOI 5 to be the optimal yeast:DC ratio leading to about 80% eGFP-positive cells (data not shown). Figure 3c shows the results for eGFP-positive DCs from four independent donors providing clear evidence that recombinant yeast cells are also capable of delivering both functional DNA and mRNA to DCs. Again, the delivery of plasmid DNA revealed high numbers of eGFP-positive DCs with a median value of about 17%. For mRNA delivery, in contrast to IC21 cells, transfection efficacy of the different promoters differed remarkably. The highest numbers of eGFP-positive DCs were obtained after delivery under transcriptional control of the inducible MLS1 promoter (median value about 20%) although we found this promoter much less and later induced than ICL1 (see Figure 1b) . ICL1 as well as constitutive mRNA formation driven from the PGK promoter turned out to be roughly equally effective with median values of about 12%. Taken together, these results strongly underline the potential of yeast in the functional delivery of nucleic acids to mammalian cells.
Antigen processing and presentation after yeast-mediated DNA/mRNA delivery To underline the usefulness of the yeast-based system for delivery of antigen-encoding DNA/mRNA, the efficient processing and presentation of the encoded protein, as well as subsequent activation of Figure 5a ). There was also a positive outcome of this modification regarding the T cell stimulating capacity of human DCs: we obtained an elevated number of activated pp65-specific T cells with a slight rise after DNA delivery (about 12%) and a more pronounced effect after mRNA delivery (about 65%; Figure 5b ). This result shows that both the yeast-delivered pp65-encoding DNA and mRNA are efficiently expressed, and the resulting protein was subsequently processed within the MHC I pathway of human DCs. Further, 3¢ modification of antigen-encoding DNA/mRNA increases translational efficacy and T cell stimulatory capacity.
DISCUSSION
The use of recombinant yeast as delivery system for nucleic acids is a novel approach to classical DNA/RNA vaccination strategies and a promising alternative in particular to already described viral and, in particular, bacterial delivery systems. 4, 27 We show, for the first time, that recombinant yeast cells are able to deliver DNA very efficiently to murine macrophages and, importantly, also to human DCs. Conveniently, the yeast-based system developed in this study is not restricted to the transfer of DNA, but can also effectively deliver functional mRNA. In the literature, the delivery of mRNA instead of DNA is favored as (i) it avoids the safety problem of integration of plasmid DNA into the host cell genome that arises as a result of DNA vaccination, (ii) it circumvents the need of plasmid DNA entry into the nucleus for high-level gene expression and (iii) it makes the use of mammalian promoters dispensable, a fact that can at least diminish the possibility of dangerous side effects. 28 Our yeast-based carrier shows a significant higher capacity at a roughly equivalent MOI than a comparable Listeria-based system in which eGFP was set under CMV promoter control for plasmid delivery and a T7 promoter for inducible mRNA delivery after phagocytosis of the bacteria by APCs. This approach led to transfection efficiencies of only about 1 or 9% DCs after DNA/mRNA delivery, respectively. 5 In this context, another exclusive advantage of yeast-mediated delivery in comparison with known systems consists in the specific targeting of the delivered nucleic acid to phagocytic cells, such as professional APCs like macrophages and DCs. In contrast, classical DNA/RNA vaccination is per se unspecific, and the majority of carriers currently under investigation (bacteria and viruses) is unable to target APCs in particular and rather infects a variety of cell types like epithelial, muscle cells and other non-APCs. 3, 4, [29] [30] [31] Taking this into account, the effective delivery of DNA by recombinant yeast regains in importance considering the danger of unwanted genomic integration of plasmid DNA into APCs in which no known potential to develop diseases like cancer exists. Likewise, the novel yeast carrier described here could also be used for therapeutic purposes in which delivery of nucleic acids into APCs is desired. Noteworthy and in strong contrast to many known bacterial or viral systems, yeast cells do neither interfere with cell growth nor cell function of mammalian APCs. 32, 33 Using CMV pp65 as a model antigen, we could also demonstrate an effective specific T cell activation in a human system after antigen processing and presentation. We preselected CMV-positive individuals with a significant frequency of CMV-specific CD8+ T cells. These individuals are rare because the CMV response is largely dominated by CD4-positive T cells. However, it is long known that in most individuals up to 95% of all CTL-recognizing CMV-infected cells are pp65 specific. 34, 35 We observed a higher number of activated CD8 T cells after yeast delivery of nucleic acids than in control reactions containing proteins from a virus lysate. This is worth noting as the immune response induced by pp65 in vitro is known to be similar to that of whole viral antigen considering T cell proliferation, as well as interleukin 2 and interferon production, [35] [36] [37] again underlining the efficacy of the yeast system. Yeast-based DNA/mRNA delivery B Walch et al Importantly, transfer of the respective nucleic acid from phagolysosomes to the cytosol of APC takes place even without the need of additional and potential toxic components such as pore-forming toxins like listeriolysin O, adding further evidence to the fact that yeast cells fulfill the preconditions of a highly efficient delivery vehicle for nucleic acids. In line with this, APCs are neither killed nor significantly impaired in growth or function after yeast cell uptake (this work and Breinig et al. 32 ), whereas attenuated bacterial carriers like Listeria monocytogenes have been repeatedly shown to be toxic to infected APCs and other cell types. 5, [38] [39] [40] So far, the mechanism of DNA/mRNA transfer from phagolysosomes to the cytosol is completely unknown. A simple rupture of the phagolysosomes seems unlikely as such an event would release lysosomal activity, which, as a consequence, would presumably affect the viability of the APCs. However, there are several reports in which proteins delivered by recombinant yeast are capable of entering in particular the MHC I pathway via crosspresentation, 11, 12, 18, 20, 32 a mechanism whose molecular basis is currently controversially discussed. One explanation for this phenomenon could be the observation that phagosomes containing exogenous proteins merge with the endoplasmic reticulum (ER) in professional APCs, such as macrophages and DCs. Subsequently, the proteins are capable of exiting the ER via pores that are normally involved in ER protein quality control (endoplasmic reticulum-associated degradation), enter the cytosol and re-enter the ER as peptides through binding to MHC I molecules. 41, 42 This raises the possibility that extra-chromosomal nucleic acids from internalized yeast cells might be able to exit phagosomes and/or the ER either unspecifically by hijacking cellular endoplasmic reticulum-associated degradation components or entering the cytosol through a specific but so far unknown mechanism to initiate transcription and/or translation.
Finally, another attractive feature of the newly developed system lies in the fact that clearly no neutralization of the vector system occurs even after repeated immunizations, 43 a well-known phenomenon that so far has hampered the use of several viral as well as bacterial vector systems. In conclusion, the novel yeast-based delivery system described here offers several advantages in comparison with established bacterial and viral carrier systems. It represents a promising and innovative approach, whose potential as vaccine carrier has to be elucidated in the near future.
MATERIALS AND METHODS
Strains, plasmids and DNA manipulations
For cloning, E. coli strain TOP10 [F À mcrA D(mrr-hsdRMS-mrcBC) f80lacZDM15 DlacX74 recA1 deoR araD139 D(ara-leu)7697 galU galK rspL (Str R ) endA1 nupG] (Invitrogen, Carlsbad, CA, USA) was grown at 37 1C in LB medium supplemented with 50 mg ml À1 ampicillin. S. cerevisiae strain S86c [MATa ura3-2 his3 pra1 prb2 prc1 cps1L-0 M-0] was grown at 30 1C in complex YEPD medium or synthetic medium (YNB) supplemented with the appropriate amino-acid/base requirements for this strain. All plasmids and oligonucleotide primers used in this study are listed in Tables 1 and 2 , respectively. The IRES-eGFP fusion was constructed by the method of splicing by overlapping extension (SOE)-PCR 44, 45 using the templates pEGFP-C1 (Clontech, Mountain View, CA, USA) and the primers 5¢-IRES-eGFP and 3¢-eGFP for amplification of eGFP. For amplification of the IRES sequence, plasmid pIRES (Clontech) was applied as template using the primers 5¢-IRES and 3¢-IRES-eGFP. For the IRES-eGFP fusion, primers 5¢-IRES and 3¢-eGFP were used. Likewise, the IRES-pp65 fusion was constructed using primers 5¢-IRES and 3¢-IRES-pp65, as well as 5¢-IRES-pp65 and 3¢-pp65, respectively, and plasmid jw4303 as template. The CMV promoter was amplified using the template pEGFP-C1 (Clontech) and the primers 5¢-CMV and 3¢-CMV. The inducible yeast promoters MLS1 and ICL1 were amplified using isolated chromosomal DNA of S. cerevisiae S86c and primers 5'-MLS1 and 3¢-MLS1, or 5¢-ICL1 and 3¢-ICL1. In preliminary induction experiments, a yeast-translatable eGFP lacking IRES was used (Figures 1a and b) . All PCR-amplified constructs were routinely sequenced and subsequently cloned into the expression vector pPGK-M28-I. 46, 47 The CMV, MLS1 and ICL1 promoter sequences were cloned as HindIII/ XhoI fragments resulting in pCMV, pMLS1 and pICL1 replacing the original PGK promoter sequence. The IRES-eGFP fusion was cloned as XhoI/BglII fragment in pCMV, pMLS1, pICL1 and pPGK-M28-I to give pCMV-IRESeGFP, pMLS1-IRES-eGFP, pICL1-IRES-eGFP and pPGK-IRES-eGFP, respectively. Alternatively, the IRES-pp65 fusion was cloned as XhoI/XbaI fragment. The SV40 poly(A) signal sequence (225 nucleotides) was amplified using plasmid pEGFP-C1 (Clontech) as template. The yeast PGK terminator was replaced by BglII/SacI restriction. Yeast cells were transformed by the lithium acetate method, 48 and transformants were selected on synthetic complete medium lacking uracil. Yeast-based DNA/mRNA delivery B Walch et al
Cell culture and preparation of human DCs
The murine macrophage-like cell line IC21 was cultured in standard RPMI 1640 medium (Sigma, St Louis, MO, USA) with L-glutamine supplemented with 10% fetal bovine serum (FBS) (PAA, Pasching, Austria) at 37 1C in a 5% (v/v) CO 2 atmosphere. DCs were generated from standard buffy coat preparations of healthy blood donors as described previously. 49 In brief, peripheral blood mononuclear cells were isolated by LSM 1077 Lymphocyte (PAA) density gradient centrifugation, and washed twice with phosphate-buffered saline (PBS). Monocytes were purified from PBL by adhesion for 2 h in RPMI medium supplemented with 10% lipopolysaccharides-free, heat-inactivated FBS (Biochrom, Berlin, Germany) at 37 1C, and washed twice with PBS. To generate immature DCs (iDCs), monocytes were cultured in standard RPMI medium supplemented with 10% FBS, 800 U ml À1 GM-CSF (Leucomax, AESCA, Traiskirchen, Austria) and 1000 U ml À1 IL-4 (Strathmann, Hamburg, Germany) for 5 days. iDCs were matured into potent T cell stimulatory mature DCs (mDCs) by addition of yeasts (see below).
Loading of IC21 macrophages and human DCs with yeast
For loading with yeast cells, murine macrophages IC21 were seeded into 24-well plates 8 h before loading with a density of 1Â10 5 cells per well in standard RPMI medium supplemented with 10% heat-inactivated FBS. Yeast strains were cultured until OD 600 ¼1. Yeasts were added at MOI 7 (unless stated otherwise) in 1 ml medium and cocultured for 16 h. Medium was removed, IC21 cells were washed once with PBS, harvested and fixed with 1% paraformaldehyde. For loading of human iDCs, yeasts were added to 1Â10 6 iDCs at MOI 5 (unless stated otherwise) in 2 ml medium, and cultured for 8 h. Medium was removed, mDCs were washed with PBS supplemented with 10% heat-inactivated FBS, and fixed with 1% paraformaldehyde. For IC21 cells, given values represent the mean of at least three independent experiments. For DCs, the median value of four independent donors (at least two parallel experiments for each donor) is given. Statistical analysis was performed using the Prism 4.01 software (Graphpad, San Diego, CA, USA).
Stimulation of pp65-specific memory T cells by autologous mDCs
The MHC I-restricted antigen-specific T cell stimulation protocol was previously described. 50 Briefly, peripheral blood mononuclear cells were separated into monocytes and PBL by adherence. PBL were kept frozen in liquid nitrogen (N 2 ) until use, whereas monocytes were differentiated into iDCs as described above. The iDCs were incubated for 48 h with yeast cells at MOI 5 in 2 ml medium. The cells were then incubated together with the autologous PBL in a 1:1 ratio in the presence of antibodies against CD49d and CD28. After 2 h, brefeldin A was added to the cells to inhibit secretion of produced cytokines. After fixation, cells were stained for intracellular IFN-g and the surface markers CD69 and CD4 or CD8, and subsequently analyzed by flow cytometry for simultaneous expression of stained markers.
Flow cytometry
Cell surface marker expression of iDCs was evaluated by double immunofluorescence staining. Briefly, DCs were washed twice with PBS supplemented with 10% FBS. Fluorescein isothiocyanate-or phycoerythrin-conjugated monoclonal antibodies specific for CD1a (Clone NA1/34), DC14 (Clone TUEK4), HLA-DR (Clone CR3/43), HLA-I (Clone W6/32, all from DAKO, Hamburg, Germany), CD80 (Clone MAB104), CD86 (Clone 2331, all from Pharmingen, San Diego, CA, USA) or CD83 (Clone HB15a, Coulter Immunotech, Krefeld, Germany) were added for 45 min on ice at the dark. After fixation with 1% paraformaldehyde, 10 000 cells were analyzed by flow cytometry. For analysis of eGFP fluorescence in mammalian cells, infected cells were washed with PBS and fixed with 1% paraformaldehyde. For each experiment, 30 000 cells (IC21 or human DCs) were counted by flow cytometry. Analysis was performed using a FACScan flow cytometer and the Cell Quest software (BD Bioscience, Heidelberg, Germany).
Cell viability assay
Cell viability was routinely assessed by light microscopy after staining of resuspended cells with an equal volume of trypan blue (Sigma; 0.4 %) for 1 min at room temperature.
Inhibition of host cell translation
The translation inhibitor cycloheximide was added to a final concentration of 5-10 mg ml À1 of IC21 cells after loading with yeasts in standard RPMI medium containing 10% FBS. Cultures were incubated for 16 h followed by flow cytometric analysis. There was no significant impairment of cell viability or uptake of yeast cells caused by cycloheximide in comparison with control cells without inhibitor (data not shown).
Fluorescence microscopy
For fluorescence microscopy, yeast cells containing the respective plasmid were grown to late exponential phase in YNB medium, washed with PBS, and checked for green fluorescence on a BX-51 microscope (Olympus, Hamburg, Germany) using standard fluorescein isothiocyanate settings.
